Business
Mesoblast treatment gets US panel’s key tick of approval – Sydney Morning Herald
The drug that Mesoblast has been trialling on some COVID-19 patients has just got the nod from a US regulator panel for treating children with severe responses to bone marrow transplants.
Stem cell treatment producer Mesoblast has recorded a significant win after the US FDA’s Oncologic Drugs Advisory Committee voted in favour of its flagship product for treating children with severe responses to bone marrow transplants.
The planned meeting of the US regulator had sent Mesoblast shares on a rollercoaster this week. The multi-billion company’s share price dropped more than 30 per cent in a single session on Tuesday after briefing papers released ahead of the meeting revealed the w…
-
Business18 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
General23 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Noosa News20 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal
-
Noosa News13 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track